Viral Vectors in Gene Therapy
Open accessThe DOI matches its Crossref record; 127 of the 128 references it cites were found in a registry or an index.
Abstract
Applications of viral vectors have found an encouraging new beginning in gene therapy in recent years. Significant improvements in vector engineering, delivery, and safety have placed viral vector-based therapy at the forefront of modern medicine. Viral vectors have been employed for the treatment of various diseases such as metabolic, cardiovascular, muscular, hematologic, ophthalmologic, and infectious diseases and different types of cancer. Recent development in the area of immunotherapy has provided both preventive and therapeutic approaches. Furthermore, gene silencing generating a reversible effect has become an interesting alternative, and is well-suited for delivery by viral vectors. A number of preclinical studies have demonstrated therapeutic and prophylactic efficacy in animal models and furthermore in clinical trials. Several viral vector-based drugs have also been globally approved.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The 5 main classes of viral vectors can be categorized in 2 groups according to whether their genomes integrate into host cellular chromatin (oncoretroviruses and LV) or persist in the cell nucleus predominantly as extrachromosomal episomes (AAV, AV, and herpes viruses).”
From Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges (2020) · cites this paper as [6]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Retroviral 3rd generation lentivirus-based systems have a larger packaging size of ~8.5 kb compared to 4.5-4.6 kb in rAAV [213].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [213]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although AV cause mild respiratory disease or conjunctivitis in healthy adults, they are notoriously immunogenic.”
From Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges (2020) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Also, many viral vectors have been employed for treating GARDs, such as hemophilia, cystic fibrosis, or rare inherited retinal diseases, etc.[23, 28]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [23]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854 · cited 7×
“Related to cancer, Coxsackievirus A21 (CAV21) expressing intercellular adhesion molecule-1 (ICAM-1) and decay-accelerating factor (DAF) reduced tumor burden in nonobese SCID mice implanted with melanoma xenografts [77].”
BackgroundInfluentialRaper, S. E., Chirmule, N., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G.-P., Wilson, J. M., & Batshaw, M. L. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.08.016 · Cited by 1,498
Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
Kay, M. A., Glorioso, J. C., & Naldini, L. (2001) · Nature Medicine · doi:10.1038/83324 · Cited by 1,342
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955 · cited 2×
“One limitation of using AAV relates to the immune response triggered by repeated administration [9].”
BackgroundHeo, J., Reid, T., Ruo, L., Breitbach, C. J., Rose, S., Bloomston, M., Cho, M., Lim, H. Y., Chung, H. C., Kim, C. W., et al. (2013) · Nature Medicine · doi:10.1038/nm.3089 · Cited by 779
Oncolytic virus therapy: A new era of cancer treatment at dawn
Fukuhara, H., Ino, Y., & Todo, T. (2016) · Cancer Science · doi:10.1111/cas.13027 · Cited by 774
Qin, X.-F., An, D. S., Chen, I. S. Y., & Baltimore, D. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.232688199 · Cited by 701
Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691 · cited 1×
“In this context, improved adenovirus vectors could be engineered for personalized drug delivery [130].”
BackgroundSchiedner, G., Morral, N., Parks, R. J., Wu, Y., Koopmans, S. C., Langston, C., Graham, F. L., Beaudet, A. L., & Kochanek, S. (1998) · Nature Genetics · doi:10.1038/ng0298-180 · Cited by 648
AAV-Mediated Gene Therapy for Research and Therapeutic Purposes
Samulski, R. J., & Muzyczka, N. (2014) · Annual Review of Virology · doi:10.1146/annurev-virology-031413-085355 · Cited by 551
Kaufman, H. L., Kim, D. W., DeRaffele, G., Mitcham, J., Coffin, R. S., & Kim-Schulze, S. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0809-6 · Cited by 518
Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model
Singer, O., Marr, R. A., Rockenstein, E., Crews, L., Coufal, N. G., Gage, F. H., Verma, I. M., & Masliah, E. (2005) · Nature Neuroscience · doi:10.1038/nn1531 · Cited by 428
Grieger, J. C., & Samulski, R. J. (2005) · Journal of Virology · doi:10.1128/jvi.79.15.9933-9944.2005 · Cited by 419
Markert, J. M., Liechty, P. G., Wang, W., Gaston, S., Braz, E., Karrasch, M., Nabors, L. B., Markiewicz, M., Lakeman, A. D., Palmer, C. A., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.228 · Cited by 401
Pecora, A. L., Rizvi, N., Cohen, G. I., Meropol, N. J., Sterman, D., Marshall, J. L., Goldberg, S., Gross, P., O’Neil, J. D., Groene, W. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.042 · Cited by 385
Vigna, E., & Naldini, L. (2000) · The Journal of Gene Medicine · doi:10.1002/1521-2254(200009/10)2:5<308::aid-jgm131>3.0.co;2-3 · Cited by 343
Markert, J. M., Razdan, S. N., Kuo, H.-C., Cantor, A., Knoll, A., Karrasch, M., Nabors, L. B., Markiewicz, M., Agee, B. S., Coleman, J. M., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.22 · Cited by 319
The First Approved Gene Therapy Product for Cancer Ad- p53 (Gendicine): 12 Years in the Clinic
Zhang, W.-W., Li, L., Li, D., Liu, J., Li, X., Li, W., Xu, X., Zhang, M. J., Chandler, L. A., Lin, H., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.218 · Cited by 318
McCormack, M. P., & Rabbitts, T. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032207 · Cited by 278
Ramesh, N., Ge, Y., Ennist, D. L., Zhu, M., Mina, M., Ganesh, S., Reddy, P. S., & Yu, D.-C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1059 · Cited by 242
Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer
Hastie, E., & Grdzelishvili, V. Z. (2012) · Journal of General Virology · doi:10.1099/vir.0.046672-0 · Cited by 226
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma
Cloughesy, T. F., Landolfi, J., Hogan, D. J., Bloomfield, S., Carter, B., Chen, C. C., Elder, J. B., Kalkanis, S. N., Kesari, S., Lai, A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9784 · Cited by 195
Silencing of CDK5 Reduces Neurofibrillary Tangles in Transgenic Alzheimer's Mice
Piedrahita, D., Hernández, I., López-Tobón, A., Fedorov, D., Obara, B., Manjunath, B. S., Boudreau, R. L., Davidson, B., LaFerla, F., Gallego-Gómez, J. C., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3637-10.2010 · Cited by 183
Silencing of human α-synuclein in vitro and in rat brain using lentiviral-mediated RNAi
Sapru, M. K., Yates, J. W., Hogan, S., Jiang, L., Halter, J., & Bohn, M. C. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2005.12.024 · Cited by 173
Lin, Y., Zhang, H., Liang, J., Li, K., Zhu, W., Fu, L., Wang, F., Zheng, X., Shi, H., Wu, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408759111 · Cited by 165
Patel, D. M., Foreman, P. M., Nabors, L. B., Riley, K. O., Gillespie, G. Y., & Markert, J. M. (2016) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2016.031 · Cited by 163
Gene therapy progress and prospects cancer: oncolytic viruses
Liu, T.-C., & Kirn, D. (2008) · Gene Therapy · doi:10.1038/gt.2008.72 · Cited by 158
Shafren, D. R., Au, G. G., Nguyen, T. P., Newcombe, N. G., Haley, E. S., Beagley, L., Johansson, E., Hersey, P., & Barry, R. D. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0690-3 · Cited by 158
Garcia-Carbonero, R., Salazar, R., Duran, I., Osman-Garcia, I., Paz-Ares, L., Bozada, J. M., Boni, V., Blanc, C., Seymour, L., Beadle, J., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0277-7 · Cited by 154
Gollamudi, R., Ghalib, M. H., Desai, K. K., Chaudhary, I., Wong, B., Einstein, M. H., Coffey, M. C., Gill, G. M., Mettinger, K. L., Mariadason, J. M., et al. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9279-8 · Cited by 152
Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis
Alton, E. W. F. W., Beekman, J. M., Boyd, A. C., Brand, J., Carlon, M. S., Connolly, M. M., Chan, M., Conlon, S., Davidson, H. E., Davies, J. C., et al. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-208406 · Cited by 150
Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers
Downs‐Canner, S., Guo, Z. S., Ravindranathan, R., Breitbach, C. J., O’Malley, M. E., Jones, H. L., Moon, A., McCart, J. A., Shuai, Y., Zeh, H. J., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.101 · Cited by 146
Adeno-associated Virus (AAV) Dual Vector Strategies for Gene Therapy Encoding Large Transgenes.
McClements, M. E., & MacLaren, R. E. (2017) · PubMed Central · Cited by 144
Muik, A., Stubbert, L. J., Jahedi, R. Z., Geiβ, Y., Kimpel, J., Dold, C., Tober, R., Volk, A., Klein, S., Dietrich, U., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3306 · Cited by 138
Design of Retroviral Vectors and Helper Cells for Gene Therapy
Hu, W.-S., & Pathak, V. K. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01467-4 · Cited by 126
Schirrmacher, V. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0602-0 · Cited by 124
Applications of coxsackievirus A21 in oncology
Bradley, S., Jakes, A. D., Harrington, K. J., Pandha, H., Melcher, A. A., & Errington‐Mais, F. (2014) · Oncolytic Virotherapy · doi:10.2147/ov.s56322 · Cited by 114
Oncolytic viruses: adenoviruses
Niemann, J., & Kühnel, F. (2017) · Virus Genes · doi:10.1007/s11262-017-1488-1 · Cited by 111
Eissa, I. R., Naoe, Y., Bustos‐Villalobos, I., Ichinose, T., Tanaka, M., Wu, Z., Mukoyama, N., Morimoto, T., Miyajima, N., Hasegawa, H., et al. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00149 · Cited by 106
Biology and application of alphaviruses in gene therapy
Lundstrom, K. H. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302620 · Cited by 100
Self-citationGene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications
Räty, J. K., Pikkarainen, J. T., Wirth, T. C., & Ylä‐Herttuala, S. (2008) · Current Molecular Pharmacology · doi:10.2174/1874-470210801010013 · Cited by 98
Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers
Zeh, H. J., & Bartlett, D. L. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700549 · Cited by 95
CCR5 Targeted Cell Therapy for HIV and Prevention of Viral Escape
Hütter, G., Bodor, J., Ledger, S., Boyd, M. P., Millington, M., Tsie, M. S., & Symonds, G. P. (2015) · Viruses · doi:10.3390/v7082816 · Cited by 95
Pfister, E. L., DiNardo, N., Mondo, E., Borel, F., Conroy, F., Fraser, C., Gernoux, G., Han, X., Hu, D., Johnson, E., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.199 · Cited by 95 · cited 2×
“AAV AAV-MeCP2 RTT MeCP2 dose-related toxicity, extended survival of mice [34] AAV1, AAV5 HD HTT miRNA gene silencing of HTT in transgenics [35] Dual AAV9 CT luciferase reporter expression in macaque lung [36] DMD mini-dystrophin mini-dystrophin expression, [38] AAV8, AAV9, hemophilia FVIII reduced muscle degeneration…”
BackgroundLiang, W., Wang, H., Sun, T.-M., Yao, W.-Q., Chen, L.-L., Jin, Y., Li, C., & Meng, F. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i3.495 · Cited by 92
Bai, F., Yu, Y.-H., Tian, H., Ren, G., Wang, H., Zhou, B., Han, X., Yu, Q., & Li, D. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.29686 · Cited by 90
PANVAC™-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma
Madan, R. A., Arlen, P. M., & Gulley, J. L. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.4.543 · Cited by 89
Csatáry, L. K., Moss, R. W., Beuth, J., Törőcsik, B., Szeberényi, J., & Bakács, T. (1999) · PubMed · Cited by 87
Gándara, C., Affleck, V., & Stoll, E. A. (2018) · Human Gene Therapy Methods · doi:10.1089/hgtb.2017.098 · Cited by 87
Ringpis, G.-E. E., Shimizu, S., Arokium, H., Camba-Colón, J., Carroll, M. V., Cortado, R., Xie, Y., Kim, P. Y., Sahakyan, A., Lowe, E. L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0053492 · Cited by 86
Slovin, S. F., Kehoe, M., Durso, R. J., Fernandez, C., Olson, W. C., Gao, J. P., Israel, R. J., Scher, H. I., & Morris, S. A. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.11.096 · Cited by 80
Kodippili, K., Hakim, C. H., Pan, X., Yang, H. T., Yue, Y., Zhang, Y., Shin, J.-H., Yang, N. N., & Duan, D. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.095 · Cited by 80
Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21
Skelding, K. A., Barry, R. D., & Shafren, D. R. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9899-2 · Cited by 75
Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector
Clarke, D. K., Cooper, D., Egan, M. A., Hendry, R. M., Parks, C. L., & Udem, S. A. (2006) · Springer Seminars in Immunopathology · doi:10.1007/s00281-006-0042-3 · Cited by 74
Cancer gene therapy using adeno-associated virus vectors
Park, K. (2008) · Frontiers in Bioscience · doi:10.2741/2872 · Cited by 72
Zhang, L., Steele, M. B., Jenks, N. J., Grell, J. A., Suksanpaisan, L., Naik, S., Federspiel, M. J., Lacy, M. Q., Russell, S. J., & Peng, K.-W. (2016) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2016.061 · Cited by 71
Therapeutic potential of oncolytic Newcastle disease virus a critical review
Zakay‐Rones, Z., Tayeb, S., & Panet, A. (2015) · Oncolytic Virotherapy · doi:10.2147/ov.s78600 · Cited by 69
Attenuation of Semliki Forest Virus Neurovirulence by MicroRNA-Mediated Detargeting
Ylösmäki, E. O., Martikainen, M., Hinkkanen, A., & Saksela, K. (2012) · Journal of Virology · doi:10.1128/jvi.01940-12 · Cited by 68
Safe and Efficient Gene Therapy for Pyruvate Kinase Deficiency
García-Gómez, M., Calabria, A., García-Bravo, M., Benedicenti, F., Kosinski, P. A., López-Manzaneda, S., Hill, C., Mañú‐Pereira, M. D. M., Martín, M. A., Orman, I., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.87 · Cited by 65
HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy
Epstein, A. L., Marconi, P., Argnani, R., & Manservigi, R. (2005) · Current Gene Therapy · doi:10.2174/156652305774329285 · Cited by 64
Vaccinia Virus, a Promising New Therapeutic Agent for Pancreatic Cancer
Yaghchi, C. A., Zhang, Z., Alusi, G., Lemoine, N. R., & Wang, Y. (2015) · Immunotherapy · doi:10.2217/imt.15.90 · Cited by 64
Huang, T., Parab, S., Burnett, R., Diago, O. R., Ostertag, D. G., Hofman, F. M., Espinoza, F. L., Martin, B., Ibañez, C. E., Kasahara, N., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.100 · Cited by 63
Peterson, C. W., Haworth, K. G., Burke, B. P., Polacino, P. S., Norman, K. K., Adair, J. E., Hu, S., Bartlett, J. S., Symonds, G. P., & Kiem, H. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.7 · Cited by 61
Waters, A. M., Johnston, J. M., Reddy, A. T., Fiveash, J. B., Madan‐Swain, A., Kachurak, K., Bag, A. K., Gillespie, G. Y., Markert, J. M., & Friedman, G. K. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.002 · Cited by 61
Development of the PANVAC™-VF vaccine for pancreatic cancer
Petrulio, C., & Kaufman, H. L. (2006) · Expert Review of Vaccines · doi:10.1586/14760584.5.1.9 · Cited by 60
Wei, Q., Fan, J., Liao, J., Zou, Y., Song, D., Liu, J., Cui, J., Liu, F., Ma, C., Hu, X., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000475909 · Cited by 60
Mansfield, D., Kyula, J., Rosenfelder, N., Chao-Chu, J., Krämer-Marek, G., Khan, A., Roulstone, V., McLaughlin, M., Melcher, A. A., Vile, R. G., et al. (2016) · Gene Therapy · doi:10.1038/gt.2016.5 · Cited by 57
Potts, K. G., Irwin, C. R., Favis, N. A., Pink, D., Vincent, K. M., Lewis, J. D., Moore, R. B., Hitt, M., & Evans, D. H. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607296 · Cited by 57
Gene therapy for severe combined immunodeficiencies
Gaspar, H. B., & Thrasher, A. J. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.9.1175 · Cited by 56
LeBlanc, A. K., Naik, S., Galyon, G. D., Jenks, N. J., Steele, M., Peng, K.-W., Federspiel, M. J., Donnell, R. L., & Russell, S. J. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.165 · Cited by 54
Replication competent Semliki Forest virus prolongs survival in experimental lung cancer
Määttä, A., Mäkinen, K. T., Ketola, A., Liimatainen, T., Yongabi, F. N., Vähä-Koskela, M. J. V., Pirinen, R. T., Rautsi, O., Pellinen, R., Hinkkanen, A., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23646 · Cited by 52
Niu, Z.-S., Bai, F., Sun, T., Tian, H., Yu, D., Yin, J., Li, S., Li, T., Cao, H., Yu, Q., et al. (2014) · Technology in Cancer Research & Treatment · doi:10.7785/tcrt.2012.500414 · Cited by 52
Poxviruses as vectors for cancer immunotherapy.
Kwak, H., Hörig, H., & Kaufman, H. L. (2003) · PubMed · Cited by 50
Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus
Illingworth, S., Di, Y., Bauzon, M., Lei-Rossmann, J., Duffy, M. R., Alvis, S., CHAMPION, B. R., Lieber, A., Hermiston, T. W., Seymour, L. W., et al. (2017) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2017.03.003 · Cited by 49
Reddi, H. V., Madde, P., McDonough, S. J., Trujillo, M. A., Morris, J. C., Myers, R. M., Peng, K.-W., Russell, S. J., McIver, B., & Eberhardt, N. L. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2012.47 · Cited by 48
Potent Oncolytic activity of human enteroviruses against human prostate cancer
Berry, L. J., Au, G. G., Barry, R. D., & Shafren, D. R. (2008) · The Prostate · doi:10.1002/pros.20741 · Cited by 47
Mastrangelo, M. J., & Lattime, E. C. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700538 · Cited by 46
An armed oncolytic measles vaccine virus eliminates human hepatoma cells independently of apoptosis
Lampe, J. W., Bossow, S., Weiland, T., Smirnow, I., Lehmann, R., Neubert, W. J., Bitzer, M., & Lauer, U. M. (2013) · Gene Therapy · doi:10.1038/gt.2013.28 · Cited by 46
A Novel Armed Oncolytic Measles Vaccine Virus for the Treatment of Cholangiocarcinoma
Lange, S., Lampe, J. W., Bossow, S., Zimmermann, M., Neubert, W. J., Bitzer, M., & Lauer, U. M. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.136 · Cited by 45
Retroviral Vectors for Cancer Gene Therapy
Schambach, A., & Morgan, M. A. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-42934-2_2 · Cited by 43
Semliki Forest virus-mediated gene therapy of the RG2 rat glioma
Roche, F. P., Sheahan, B. J., O’Mara, S. M., & Atkins, G. J. (2010) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01110.x · Cited by 42
Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride
Skelding, K. A., Barry, R. D., & Shafren, D. R. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9614-0 · Cited by 42
Zhou, S., Fatima, S., Ma, Z., Wang, Y.-D., Lu, T., Janke, L. J., Du, Y., & Sorrentino, B. P. (2016) · Molecular Therapy · doi:10.1038/mt.2016.55 · Cited by 42
Lundstrom, K. H. (2018) · Biologics · doi:10.2147/btt.s140114 · Cited by 42
Self-citationGreig, J. A., Wang, Q., Reicherter, A. L., Chen, S.-J., Hanlon, A. L., Tipper, C. H., Clark, K. R., Wadsworth, S., Wang, L., & Wilson, J. M. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.128 · Cited by 40
Hoang-Le, D., Smeenk, L., Anraku, I., Pijlman, G. P., Wang, X. J., de Vrij, J., Liu, W., Le, T. T., Schroder, W. A., Khromykh, A. A., et al. (2008) · Gene Therapy · doi:10.1038/gt.2008.169 · Cited by 39
Andtbacka, R. H. I., Curti, B. D., Hallmeyer, S., Feng, Z., Paustian, C. C., Bifulco, C. B., Fox, B. A., Grose, M., & Shafren, D. R. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-p343 · Cited by 39
Thakur, V., Gonzalez, M. A., Pennington, K., & Chattopadhyay, M. (2016) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2016.01.006 · Cited by 39
Wang, F., Wang, Z., Tian, H., Qi, M., Zhai, Z., Li, S., Li, R., Zhang, H., Wang, W., Fu, S., et al. (2012) · Current Gene Therapy · doi:10.2174/156652312800099599 · Cited by 38
Wu, Y., He, J., Geng, J., An, Y., Ye, X., Yan, S., Yu, Q., Yin, J., Zhang, Z., & Li, D. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.02.042 · Cited by 38
Hartkopf, A. D., Bossow, S., Lampe, J. W., Zimmermann, M., Taran, F., Wallwiener, D. R., Fehm, T. N., Bitzer, M., & Lauer, U. M. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.05.004 · Cited by 36
State of the art: gene therapy of haemophilia
Spencer, H. T., Riley, B. E., & Doering, C. B. (2016) · Haemophilia · doi:10.1111/hae.13011 · Cited by 36 · cited 3×
“Likewise, stem cell-based lentiviral gene therapy can provide life-long production of FVIII and the potential cure of hemophilia A [89].”
BackgroundSilk, A. W., Kaufman, H., Gabrail, N., Mehnert, J., Bryan, J., Norrell, J., Medina, D., Bommareddy, P., Shafren, D., Grose, M., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct026 · Cited by 36
Lentiviral Vector-Mediated RNA Silencing in the Central Nervous System
Hutson, T. H., Foster, E., Moon, L. D. F., & Yáñez‐Muñoz, R. J. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.016 · Cited by 35
Treatment of colon cancer with oncolytic herpes simplex virus in preclinical models
Yang, H., Peng, T., Li, J., Wang, Y., Zhang, W., Zhang, P., Peng, S. L., Du, T., Li, Y., Yan, Q., et al. (2016) · Gene Therapy · doi:10.1038/gt.2016.15 · Cited by 32
Yamamoto, Y., Nagasato, M., Rin, Y., Henmi, M., Ino, Y., Yachida, S., Ohki, R., Hiraoka, N., Tagawa, M., & Aoki, K. (2017) · Cancer Medicine · doi:10.1002/cam4.1185 · Cited by 32
Recent endeavors in MECP2 gene transfer for gene therapy of Rett syndrome.
Sinnett, S. E., & Gray, S. J. (2017) · PubMed · Cited by 32
Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer
Chai, Z., Zhang, P., Fu, F., Zhang, X., Liu, Y., Hu, L., & Li, X. (2014) · Virology Journal · doi:10.1186/1743-422x-11-84 · Cited by 31
Holmes, K. D., Cassam, A. K., Chan, B. M. C., Peters, A. A., Weaver, L. C., & Dekaban, G. A. (2000) · Journal of NeuroVirology · doi:10.3109/13550280009006380 · Cited by 31
Oncolytic Alphaviruses in Cancer Immunotherapy
Lundstrom, K. H. (2017) · Vaccines · doi:10.3390/vaccines5020009 · Cited by 29
Self-citationPanek, W. K., KANE, J. R., Young, J. S., Rashidi, A., Kim, J. W., Kanojia, D., & Lesniak, M. S. (2017) · Oncotarget · doi:10.18632/oncotarget.20810 · Cited by 29
Stein, S., Scholz, S., Schwäble, J., Sadat, M., Modlich, U., Schultze‐Strasser, S., Diaz, M., Chen-Wichmann, L., Müller-Kuller, U., Brendel, C., et al. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.019 · Cited by 28
Guggino, W. B., Benson, J. M., Seagrave, J., Yan, Z., Engelhardt, J. F., Gao, G., Conlon, T. J., & Cebotaru, L. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.067 · Cited by 28
Gene Therapy for Hemophilia: Progress to Date
Chapin, J. C., & Monahan, P. E. (2017) · BioDrugs · doi:10.1007/s40259-017-0255-0 · Cited by 26
Voit, C. A., Kron, M., Schwürzer‐Voit, M., & Sterry, W. (2003) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1046/j.1610-0387.2003.02014.x · Cited by 25
Srinivasakumar, N. (2001) · Somatic Cell and Molecular Genetics · doi:10.1023/a:1021074613196 · Cited by 24
Ady, J., Johnsen, C., Mojica, K. M., Heffner, J., Love, D. K., Pugalenthi, A., Belin, L. J., Chen, N. G., Yu, Y., Szalay, A. A., et al. (2015) · Surgery · doi:10.1016/j.surg.2015.03.044 · Cited by 21
Knockdown of GAD67 protein levels normalizes neuronal activity in a rat model of Parkinson's disease
Horvath, L., van Marion, I., Taï, K., Nielsen, T. T., & Lundberg, C. (2011) · The Journal of Gene Medicine · doi:10.1002/jgm.1555 · Cited by 21
Cowpox Virus: A New and Armed Oncolytic Poxvirus
Ricordel, M., Foloppe, J., Pichon, C., Sfrontato, N., Antoine, D., Tosch, C., Cochin, S., Cordier, P., Quéméneur, É., Camus-Bouclainville, C., et al. (2017) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2017.08.003 · Cited by 21
Kusabuka, H., Fujiwara, K., Tokunaga, Y., Hirobe, S., Nakagawa, S., & Okada, N. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.03.054 · Cited by 20
Cancer terminator viruses (CTV): A better solution for viral‐based therapy of cancer
Emdad, L., Das, S. K., Wang, X., Sarkar, D., & Fisher, P. B. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26421 · Cited by 19
Suwanmanee, T., Ferris, M. T., Hu, P., Gui, T., Montgomery, S. A., de Villena, F. P., & Kafri, T. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.03.009 · Cited by 18
Tsuji, T., Yoneda, A., Matsuzaki, J., Miliotto, A. J., Ryan, C., Koya, R. C., & Odunsi, K. O. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0434 · Cited by 18
Nagasato, M., Rin, Y., Yamamoto, Y., Henmi, M., Hiraoka, N., Chiwaki, F., Matsusaki, K., Tagawa, M., SASAKI, H., & Aoki, K. (2017) · Anticancer Research · doi:10.21873/anticanres.11730 · Cited by 17
Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy
Yue, Y., Binalsheikh, I. M., Leach, S. B., Domeier, T. L., & Duan, D. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1124039 · Cited by 16
Self-replicating Rna Viral Vectors in Vaccine Development and Gene Therapy
Lundstrom, K. H. (2016) · Future Virology · doi:10.2217/fvl-2016-0028 · Cited by 16
Self-citationPressing diseases that represent promising targets for gene therapy.
Beitelshees, M., Hill, A. B., Rostami, P., Jones, C. H., & Pfeifer, B. A. (2017) · PubMed · Cited by 12
Dodd, M., Marquez‐Curtis, L. A., Janowska‐Wieczorek, A., & Hortelano, G. (2014) · The Journal of Gene Medicine · doi:10.1002/jgm.2769 · Cited by 11
CLINICAL DEVELOPMENT OF A THIRD-GENERATION ONCOLYTIC HSV-1 (G47Δ) FOR MALIGNANT GLIOMA
Ino, Y., & Todo, T. (2010) · Gene Therapy and Regulation · doi:10.1142/s1568558610000185 · Cited by 10
Novel immunotherapeutic approaches in targeting dendritic cells with virus vectors
Pereira, B. D. A., & Fraefel, C. (2015) · PubMed · doi:10.5167/uzh-114758 · Cited by 10
Latest Trends in Cancer Therapy Applying Viral Vectors
Lundstrom, K. H. (2017) · Future Virology · doi:10.2217/fvl-2017-0070 · Cited by 10
Self-citationPandha, H., Harrington, K. J., Ralph, C., Melcher, A. A., Grose, M., & Shafren, D. R. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-p341 · Cited by 9
Recent Advances in Preclinical Developments Using Adenovirus Hybrid Vectors
Ehrke‐Schulz, E., Zhang, W., Gao, J. J., & Ehrhardt, A. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.140 · Cited by 9
Coxsackievirus B3 used as a gene therapy vector to express functional FGF2
Kim, D.-S., Kim, S., Shim, S.-H., Kim, C. G., Song, M., Kim, Y.-H., Jung, Y.-W., & Jh, N. (2011) · Gene Therapy · doi:10.1038/gt.2011.201 · Cited by 8
Targeted Delivery of Growth Factors by HSV-Mediated Gene Transfer for Peripheral Neuropathy
Chattopadhyay, M. (2013) · Current Gene Therapy · doi:10.2174/156652321305131212123237 · Cited by 5
Human Vaccines & Immunotherapeutics: News
Riedmann, E. M. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.36241 · Cited by 5
An Insight into Poliovirus Biology
Crainic, R., Couderc, T., Martin, A., Wychowski, C., Girard, M. P., & Horaud, F. (1989) · Advances in experimental medicine and biology · doi:10.1007/978-1-4684-5712-4_8 · Cited by 2
Cited by
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Chitosan: A Potential Biopolymer in Drug Delivery and Biomedical Applications
Desai, N., Rana, D., Salave, S., Gupta, R., Patel, P., Karunakaran, B., Sharma, A., Giri, J., Benival, D., & Kommineni, N. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041313 · Cited by 628
CRISPR-Cas9 DNA Base-Editing and Prime-Editing
Kantor, A., McClements, M., & MacLaren, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176240 · Cited by 462
The approved gene therapy drugs worldwide: from 1998 to 2019
Ma, C.-C., Wang, Z.-L., Xu, T., He, Z.-Y., & Wei, Y.-Q. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107502 · Cited by 310
O’Flaherty, R., Bergin, A., Flampouri, E., Mota, L. M., Obaidi, I., Quigley, A., Xie, Y., & Butler, M. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107552 · Cited by 277
Metadata
- Authors
- Lundstrom, K.
- Affiliations
- PanTherapeutics, CH1095 Lutry, Switzerland
- Corresponding author
- Lundstrom, Kenneth
- ORCID
- Lundstrom, Kenneth
- Venue
- Diseases
- Publisher
- MDPI AG
- Published
- 2018-05-21
- Volume
- 6
- Issue
- 2
- Pages
- 42
- ISSN
- 2079-9721 (ISSN-L)
- PMC
- PMC6023384
- OpenAlex
- W2804535713
- Cited by
- 469
- References
- 128
- Citations by year
- 2026: 19 · 2025: 43 · 2024: 56 · 2023: 60 · 2022: 62 · 2021: 88 · 2020: 88 · 2019: 50 · 2018: 3
- FWCI
- 8.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diseases (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- viral vectors, gene therapy, vector engineering, gene delivery, vector safety, immunotherapy, gene silencing, cancer gene therapy, clinical trials, preclinical animal models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.